Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey
Authors:
- Hanan M. FathiHFHanan M. Fathi
- Iman I. El GazzarIGIman I. El Gazzar
- Mervat I. Abd ElazeemMEMervat I. Abd Elazeem
- Enas AboulKheirEAEnas AboulKheir
- Nada M. GamalNGNada M. Gamal
- Faten IsmailFIFaten Ismail
- Rawhya R. El ShereefRSRawhya R. El Shereef
- Samar TharwatSTSamar Tharwat
- Shereen ElwanSEShereen Elwan
- Nermeen SamyNSNermeen Samy
- Noha Abdel BakiNBNoha Abdel Baki
- Nora Y. ElsaidNENora Y. Elsaid
- 16 April 2022
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 989-998
Abstract
The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection (p = 0.19) or AEs post-vaccine (p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.Keywords
This publication has 40 references indexed in Scilit:
- Surveillance for Adverse Events After COVID-19 mRNA VaccinationJAMA, 2021
- Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from EgyptRheumatology International, 2021
- Predictors of Health-Care Workers’ Unwillingness to Continue Working During the Peak of COVID-19 in Western Ethiopia: An Extended Parallel-Process Model StudyRisk Management and Healthcare Policy, 2021
- Potential Interaction Between SARS-CoV-2 and Thyroid: A ReviewEndocrinology, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Adjuvants for Coronavirus VaccinesFrontiers in Immunology, 2020
- Rheumatologists’ practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in EgyptRheumatology International, 2020
- Egypt’s groundwork blessing during the COVID-19 pandemic curse: Rheumatologic experienceEuropean Journal of Rheumatology, 2020
- Rheumatology in Egypt: back to the futureRheumatology International, 2018
- Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES)Journal of Medical Internet Research, 2004